Curis (CRIS) Competitors $1.68 -0.03 (-1.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.72 +0.05 (+2.68%) As of 09/5/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. FBIO, SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and INCYShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and Incyte (INCY). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte Curis (NASDAQ:CRIS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends. Is CRIS or FBIO more profitable? Fortress Biotech has a net margin of -24.84% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Curis-341.24% N/A -102.22% Fortress Biotech -24.84%-301.81%-27.48% Do insiders & institutionals hold more shares of CRIS or FBIO? 30.0% of Curis shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 5.5% of Curis shares are owned by insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer CRIS or FBIO? In the previous week, Fortress Biotech had 2 more articles in the media than Curis. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for Curis. Fortress Biotech's average media sentiment score of 0.56 beat Curis' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortress Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRIS or FBIO? Curis currently has a consensus price target of $17.00, suggesting a potential upside of 911.90%. Fortress Biotech has a consensus price target of $16.50, suggesting a potential upside of 344.74%. Given Curis' higher possible upside, research analysts clearly believe Curis is more favorable than Fortress Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, CRIS or FBIO? Curis has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.91M1.92-$43.39M-$4.88-0.34Fortress Biotech$57.67M1.91-$46M-$1.05-3.53 Which has more volatility and risk, CRIS or FBIO? Curis has a beta of 3.81, indicating that its share price is 281% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. SummaryFortress Biotech beats Curis on 9 of the 15 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.37M$3.12B$5.77B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-0.3420.9775.5426.08Price / Sales1.92290.04480.4288.30Price / CashN/A44.9736.9659.01Price / Book-2.379.8611.446.09Net Income-$43.39M-$53.47M$3.28B$266.14M7 Day Performance0.60%2.92%0.96%0.44%1 Month Performance0.60%9.83%7.83%4.55%1 Year Performance-66.27%15.97%62.64%26.15% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.1004 of 5 stars$1.68-1.8%$17.00+911.9%-67.6%$21.37M$10.91M-0.3460FBIOFortress Biotech3.0497 of 5 stars$2.58+6.6%$16.50+539.5%+100.5%$76.77M$57.67M-2.46170Gap UpHigh Trading VolumeSABSSAB Biotherapeutics3.3143 of 5 stars$2.08-1.0%$11.00+428.8%-21.7%$21.66M$1.32M-0.52140News CoverageShort Interest ↓BOLTBolt Biotherapeutics3.1026 of 5 stars$5.29-0.3%$47.50+798.8%-60.1%$9.85M$7.69M-0.2090News CoveragePositive NewsAnalyst RevisionGap DownAMGNAmgen4.7392 of 5 stars$287.71+0.7%$304.43+5.8%-12.6%$154.89B$33.42B23.5228,000Positive NewsAnalyst ForecastGILDGilead Sciences4.9661 of 5 stars$112.97+0.4%$115.39+2.1%+46.1%$140.17B$28.75B22.5017,600Positive NewsVRTXVertex Pharmaceuticals4.9689 of 5 stars$391.02-0.3%$497.10+27.1%-15.5%$100.25B$11.02B27.956,100Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.7365 of 5 stars$580.70+0.2%$817.67+40.8%-50.2%$61.55B$14.20B14.6315,106Positive NewsAnalyst UpgradeALNYAlnylam Pharmaceuticals3.7939 of 5 stars$446.51-1.3%$405.33-9.2%+79.7%$58.53B$2.25B-180.772,230Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.7704 of 5 stars$132.22-0.3%$185.74+40.5%-30.3%$19.39B$9.68B12.647,605Trending NewsAnalyst ForecastINCYIncyte4.6152 of 5 stars$84.61+1.1%$81.60-3.6%+37.6%$16.52B$4.24B19.232,617Positive NewsAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Incyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
